Le Lézard
Classified in: Health, Covid-19 virus
Subject: SVY

Global Antiviral Drugs Market 2020-2024: Insights & Forecast with Potential Impact of COVID-19 - Leading Players are J&J, Merck & Co., AbbVie, Bristol-Myer Squibb, Gilead Sciences and Cipla


DUBLIN, Nov. 27, 2020 /PRNewswire/ -- The "Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global antiviral drugs market is expected to reach US$ 70.95 billion in 2024, increasing at a CAGR of 2.10%, for the duration of 2020-2024.

The factors such as the increasing prevalence of HIV infections, an upswing in international tourism, growth in geriatric population, increasing pharmaceutical R&D spending, rapid urbanization, upsurge in healthcare spending and growing awareness about various viral diseases are expected to drive the growth of the market.

However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations. A few notable trends may include accelerating growth rate of infectious diseases, increasing focus on telehealth, growth in pharmaceutical Merger & acquisitions and the emergence of new infectious diseases.

The global antiviral drugs market is fragmented into branded drugs and generic drugs. Branded drugs dominate the market owing to the increased levels of trust and reliability associated with branded pharmaceutical companies among customers. However, generic drugs are also gaining widespread popularity among customers due to the low-cost factor, which is likely to raise its share in the global market in the coming years.

The fastest-growing regional market was North America owing to the presence of key players in the region, availability of sophisticated healthcare infrastructure and increasing awareness of viral diseases among people. Whereas, Europe and Asia Pacific also contributed to significant shares in the global market due to the factors such as an increase in the patient pool of various infectious diseases and rise in the acceptance of generic drugs. However, the sudden outbreak of COVID-19 has caused a major disruption all across the world, which is leading to the massive demand for antiviral drugs for the management of infected coronavirus patients, providing the growth opportunity to the market globally.

Scope of the report:

Key Target Audience:

Key Topics Covered:

1. Overview
1.1 Introduction
1.2 Viral Life Cycle
1.3 Antiviral Agents
1.4 Development of Antiviral Drugs
1.5 Some Major Antiviral Compounds

2. Impact of COVID-19
2.1 Rise in COVID-19 Death Toll
2.2 Growth in Government Spending on Healthcare
2.3 COVID-19 Antiviral Candidate Drugs in Trial
2.4 Regional Impact

3. Remdesivir and COVID-19
3.1 Remdesivir
3.2 Major Clinical Studies of Remdesivir
3.3 Emergency Use of Remdesivir

4. Global Market Analysis
4.1 Global Antiviral Drugs Market by Value
4.2 Global Antiviral Drugs Market Forecast by Value
4.3 Global Antiviral Drugs Market Value by Type
4.3.1 Global Branded Antiviral Drugs Market by Value
4.3.2 Global Branded Antiviral Drugs Market Forecast by Value
4.3.3 Global Generic Antiviral Drugs Market by Value
4.3.4 Global Generic Antiviral Drugs Market Forecast by Value
4.4 Global Antiviral Drugs Market Value by Application
4.4.1 Global Hepatitis Antiviral Drugs Market by Value
4.4.2 Global Hepatitis Antiviral Drugs Market Forecast by Value
4.4.3 Global HIV Antiviral Drugs Market by Value
4.4.4 Global HIV Antiviral Drugs Market Forecast by Value
4.4.5 Global Influenza Antiviral Drugs Market by Value
4.4.6 Global Influenza Antiviral Drugs Market Forecast by Value
4.4.7 Global Herpes Antiviral Drugs Market by Value
4.4.8 Global Herpes Antiviral Drugs Market Forecast by Value
4.5 Global Antiviral Drugs Market Value by Regions

5. Regional Market Analysis
5.1 North America
5.1.1 North America Antiviral Drugs Market by Value
5.1.2 North America Antiviral Drugs Market Forecast by Value
5.1.3 North America Antiviral Drugs Market by Region
5.1.4 The U.S. Antiviral Drugs Market by Value
5.1.5 The U.S. Antiviral Drugs Market Forecast by Value
5.1.6 The U.S. Antiviral Drugs Market by Type
5.1.7 The U.S. Branded Antiviral Drugs Market by Value
5.1.8 The U.S. Branded Antiviral Drugs Market Forecast by Value
5.1.9 The U.S. Generic Antiviral Drugs Market by Value
5.1.10 The U.S. Generic Antiviral Drugs Market Forecast by Value
5.2 Europe
5.3 Asia Pacific
5.4 Middle East & Africa
5.5 Latin America

6. Market Dynamics
6.1 Growth Drivers
6.1.1 Increasing Prevalence of HIV Infections
6.1.2 Upswing in International Tourism
6.1.3 Growth in Geriatric Population
6.1.4 Increasing Pharmaceutical R&D Spending
6.1.5 Rapid Urbanization
6.1.6 Upsurge in Healthcare Expenditures
6.1.7 Growing Awareness About Various Viral infections and Diseases
6.2 Key Trends and Developments
6.2.1 Accelerating Growth Rates of Infectious Diseases
6.2.2 Increasing Focus on Telehealth
6.2.3 Growth in Pharmaceutical and Biotech Merger & Acquisition
6.2.4 Emergence of Various Pandemic Diseases
6.3 Challenges
6.3.1 High Cost Involved in Drug Development
6.3.2 Threats Associated with Drugs Counterfeiting
6.3.3 Stringent Government Regulations

7. Competitive Landscape
7.1 Global Market
7.1.1 Key Players - Revenue Comparison
7.1.2 Key Players - R&D Expenditure Comparison
7.1.3 Key Players - Market Capitalization Comparison

8. Company Profiles
8.1 Johnson & Johnson
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategies
8.2 Merck and Co.
8.3 AbbVie Inc.
8.4 Bristol-Myers Squibb
8.5 Gilead Sciences
8.6 Cipla

For more information about this report visit https://www.researchandmarkets.com/r/45eg5h

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 18:50
In response to the unprecedented challenges that Latin America has faced during various health crises such as AH1N1, Zika, COVID-19, and Dengue, a prominent group of former health ministers and public health academics from the region has published in...

at 18:00
Simply Better Brands Corp. ("SBBC" or the "Company") announces that, further to the Company's news release dated January 25, 2023, and in connection with the Branding Earnout Agreement dated January 25, 2023, the Company has issued 89,966 common...

at 16:35
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Chegg, Inc. . Chegg is a publicly traded educational technology...

at 16:30
Today, the Biden-Harris Administration released a final rule under Section 1557, the core nondiscrimination provision of the Affordable Care Act. This groundbreaking rule marks a critical step in protecting access to health care and coverage for...

at 16:30
Farmmi, Inc. ("Farmmi" or the "Company") , an agriculture products supplier in China, today announced that on April 22, 2024, it received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is currently not in...

at 16:20
AMC Entertainment Holdings, Inc. (the "Company," or "AMC"), today released preliminary results for the first quarter ended March 31, 2024. The preliminary results are unaudited, subject to completion of the Company's financial reporting processes,...



News published on and distributed by: